| 摘要 |
1. The use of combination of angiotensin converting enzyme (ACE) inhibitor and diuretic for obtaining pharmaceutical compositions for treatment of arteriolo capillary microcirculation loss. 2. The use according to Claim 1, characterized in that angiotensin converting enzyme (ACE) inhibitor is perindopril, captopril, enalapril, lisinopril, delapril, fosinopril, quinapril, ramipril, spirapril, imidapril, trandolapril, benazepril, cilazapril or temocapril and diuretic is indapamide, hydrochlorothiazide, furosemide, altizide, trichlormethiazide, triflumethazide, bemetizide, cyclothiazide, methylclothiazide, azosemide, chlorothiazide, butizide, bendrofluazide, cyclopenthiazide, benzchlortriazide, polythiazide, hydroflumethazide, benzthiazide, ethiazide, penflutazide, clopamide, cicletanide or piretanide, as well as addition salts thereof, formed with pharmaceutically acceptable acid or base. 3. The use according to Claim 1, characterized in that angiotensin converting enzyme (ACE) inhibitor is perindopril, captopril, enalapril, lisinopril, benazepril, quinapril or delapril and diuretic is indapamide, hydrochlorothiazide, as well as addition salts thereof with pharmaceutically acceptable acid or base. 4. The use of combination of perindopril converting enzyme inhibitor and one of its addition salts of pharmaceutically acceptable base, and diuretic is indapamide for obtaining pharmaceutical composition for treatment of arteriolo capillary microcirculation loss. 5. The use according to Claim 4, characterized in that converting enzyme inhibitor is tert-butylamine salt of perindopril and diuretic is indapamide. 6. The use according to Claim 4, characterized in that pharmaceutical composition comprises tert-butylamine salt of perindopril and indapamide in amounts respectively from 65 to 85% and from 35 to 15 % counting on active principles mass. 7. The use according to Claim 6, characterized in that the composition comprises tert-butylamine salt of perindopril in the amount of 76 % and indapamide in the amount of 24 %. 8. The use according to Claim 1, characterized in that pharmaceutical composition is in the form of tablets. 9. The use according to Claim 4, characterized in that pharmaceutical composition is in the form of tablets. 10. The pharmaceutical composition for use according to Claim 9, characterized in that a tablet comprises 2 mg of tert-butylamine salt of perindopril and 0,625 mg of indapamide and pharmaceutically acceptable non-toxic, inert diluents or carriers. 11. The pharmaceutical composition for use according to Claim 9, characterized in that a tablet comprises 4 mg of tert-butylamine salt of perindopril and 1,25 mg of indapamide and pharmaceutically acceptable non-toxic, inert diluents or carriers. |
